Какова цена за Ceryvyn Therapeutics Ltd (OPT)

Цена за Ceryvyn Therapeutics Ltd (OPT) Это $0.00846342

Какова рыночная капитализация для Ceryvyn Therapeutics Ltd (OPT)

Рыночная капитализация для Ceryvyn Therapeutics Ltd (OPT) Это $11.27M

Ceryvyn Therapeutics Ltd (OPT) Операционная маржа

Opthea Limited is an Australian clinical-stage biopharmaceutical company focused on developing and commercializing therapies primarily for eye diseases. The foundation of its development efforts lies in its intellectual property portfolio, which targets Vascular Endothelial Growth Factors (VEGF-C, VEGF-D, and VEGF Receptor-3). This technology is designed to address conditions linked to the growth of blood and lymphatic vessels, as well as vascular leakage. The company's leading asset, OPT 302, is a soluble form of VEGFR3 currently undergoing clinical trials. This novel therapy aims to treat wet neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME). OPT 302 is distinguished as a first-in-class VEGF-C/D inhibitor, intended to be used in conjunction with VEGF-A inhibitors for the treatment of wet AMD and various other retinal diseases. Originally incorporated in 1984 as Circadian Technologies Limited, the company rebranded to Opthea Limited in December 2015 and is headquartered in South Yarra, Australia.

Год	Операционная маржа	Изменить
Недостаточно данных для указанных дат.

Год

Операционная маржа

Изменить

Недостаточно данных для указанных дат.

Компания	Операционная маржа	Разница в операционной марже	Страна
Vertex Pharmaceuticals Incorporated VRTX.US	38.59%	-	US
Argenx SE ARGX.US	28.81%	-	NL
CSL Limited CSL.AX	25.72%	-	AU
Lonza Group AG LONN.SW	0.00%	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	0.00%	-	KR

Компания

Операционная маржа

Разница в операционной марже

Страна